bluuebunny/crossref_metadata_2025_split huggingface dataset:
P2-17-09: A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen.
Authors: Lintermans A , Dieudonné A-S , Vanderhaegen J , Henry NL , Laenen A , Wildiers H , Paridaens R , Christiaens M-R , Smeets A , Leunen K , Amant F , Vergote I , Neven P 
Published: June 2012

Abstract
Background The 3rd generation aromatase inhibitors (AIs) induce or enhance musculoskeletal problems. Underlying mechanisms are probably multiple, but remain unknown. We have previously reported that loss of grip strength together with tenosynovial abnormalities are more important in AI- than in tamoxifen-users (Morales et al, JCO 2008) and that musculoskeletal changes in AI-users are more pronounced in women with extremes in baseline BMI (Lintermans et al, Ann Oncol 2011) We here report preliminary results from a larger population and plan to validate findings in patients from University of Michigan.
Patients and methods In this prospective observational study, postmenopausal early breast cancer patients scheduled to start adjuvant hormonal therapy with any of the third generation AIs or tamoxifen were recruited. After providing informed consent, a functional assessment test of grip strength was performed with a modified sphygmomanometer. Re-evaluation was done after 3, 6 and 12 months of therapy. BMI and waist to hip ratio (WHR) were assessed and a rheumatological questionnaire was completed at each visit.
Results Ninety-four (79 AI; 15 tamoxifen) of the planned 200 patients were included in this preliminary study. 18% of AI-users discontinued their treatment due to musculoskeletal symptoms compared with none of the tamoxifen-users. 62% of patients on AI and 35% of tamoxifen patients complained of new or worsened joint pain. Table 1 shows the proportion of patients that attribute their complaints to their endocrine therapy. Grip strength significantly decreased over time (p=0.03), with patients under AI treatment having a larger loss of grip strength than patients under tamoxifen treatment (p=0.04). We confirm our previously reported results on the shape of the curve “BMI AI-induced loss of grip strength”. Years past menopause and age showed a significant effect on grip strength (p&lt;0.001 and p=0.0007, respectively), whereas no significant relationship was found between WHR with grip strength or joint pain. Detailed results will be presented.

Conclusion Our preliminary results confirm that a majority of patients treated with an AI experience musculoskeletal problems, which are considered due to the therapy by most patients. Grip strength decreased over time, with a significantly larger loss of grip strength in the AI-users compared with the tamoxifen-users. AI-induced loss of grip strength and baseline BMI showed an inverted U-shaped association, although differences between quartiles were small. Further results should be awaited as this is only a preliminary analysis.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-17-09.
P3-16-17: The Identification of Novel Microtubule Stabilizing Taccalonolides.
Authors: Risinger AL , Li J , Peng J , Chen Z , Mooberry SL 
Published: June 2012

Abstract
Microtubule stabilizing agents, including the taxanes and epothilones, are some of the most important drugs used in the treatment of cancer. All of the microtubule stabilizers used clinically bind within the taxane site on microtubules and work through a similar mechanism of action. We have identified a new class of microtubule stabilizers, the taccalonolides, from plants of the genus Tacca. The most abundant taccalonolides, A and E, are classified as microtubule stabilizers due to their ability to disrupt both interphase and mitotic cellular microtubules, leading to mitotic arrest and apoptosis. However, they are unique from all other microtubule stabilizers in that they do not bind directly to microtubules or stimulate the polymerization of tubulin in biochemical preparations. The taccalonolide structure is characterized by a highly acetylated pentacyclic steroidal skeleton, which is also structurally distinct from all other microtubule targeted agents. The unique structure and mechanism of action of the taccalonolides, together with their ability to circumvent clinically relevant forms of taxane resistance, prompted our efforts to explore the structure-activity relationship of this class of molecules. We have isolated several novel taccalonolides, designated Z, AA, AB, AC, AF and AG, as well as multiple known taccalonolides. Each of these taccalonolides exhibited cellular microtubule stabilizing activity and antiproliferative actions against breast cancer cells. However, profound differences in potencies were noted with IC50 values ranging from 32 nM to 13 μM. These studies demonstrate that microtubule stabilizing activity is a shared trait among this class of molecules and that significant structure-activity relationships exist. Additionally, in vivo antitumor evaluations of taccalonolides A, E and N demonstrate that each of these molecules has activity in vivo and that taccalonolide A is the most effective against a syngeneic mammary model of breast cancer.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-16-17.
P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity.
Authors: Ligibel JA , Segal R , Pond G , Dion M-J , Pritchard KI , Levine M , Goodwin PJ 
Published: June 2012

Abstract
Observational evidence shows a relationship between obesity and poor prognosis in breast cancer (BC). Physical activity (PA) is an important component of weight loss and maintenance, but most large-scale interventions in BC patients have produced only modest improvements in activity. We sought to evaluate changes in PA in women participating in LISA, a randomized trial coordinated by the Ontario Clinical Oncology Group which was designed to examine the impact of a telephone-based weight loss intervention (WLI) upon disease free survival in BC patients.
Methods: Participants were randomized 1:1 to the WLI or educational control (EC) group. Eligibility included diagnosis of Stage I-III BC, BMI ≥24 kg/m2, and treatment with letrozole. The WLI, based on the Diabetes Prevention Program, focused on weight reduction through calorie restriction and increased physical activity. Delivery involved 19 calls, mailings and a participant manual. The PA goal was 150 minutes/week. PA was measured using the International Physical Activity Questionnaire (Short Form) at baseline, 6, 12, and 18 months. Changes in time (minutes/week) spent sitting and engaging in moderate, vigorous, and walking activities were compared between groups.
Results 338 women were randomized to WLI (n=171) or EC (n=167) from 20 centers in Canada and the USA. The study was discontinued due to loss of funding. The WLI arm lost significantly more weight than EC arm, with mean weight loss of 6.1% of body weight vs. 0.6% at 12 months (p&lt;0.001). Activity data are presented in Table 1. At baseline, participants were inactive; median vigorous activity was zero minutes/week and median time spent sitting was more than 35 hours/week. WLI participants reported significantly higher participation in vigorous, moderate and walking activities, and lower levels of sedentary behavior, compared to controls at 6 and 12 months. Higher levels of PA were significantly associated with increased weight loss at all time periods. Factors associated with increases in activity included higher baseline BMI (p=0.014), lower baseline activity (p&lt;0.001) and assignment to the WLI arm (p=0.02). Women assigned to WLI increased their PA during the intervention period (p=0.017) even after adjusting for other significant baseline factors.
Conclusion Participants in the LISA WLI reported significantly higher levels of PA compared with controls. Activity increased most in women who were heavier and less active at baseline. Further study of this WLI as a potential means to improve BC outcomes is warranted.

Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-12-05.
PD07-01: Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study.
Authors: Janni WJ , Harbeck N , Sommer H , Rack B , Salmen J , Augustin D , Simon W , Jueckstock J , Wischnik A , Anneke K , Melcher C , Friese K , Kiechle M 
Published: June 2012

Abstract
Background: Based on meta-analytic evidence, taxane containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. However, in the MA-21 study, adriamycin-cyclophosphamide, followed by paclitaxel (AC-P) was significantly inferior to the gold standard of anthracycline treatment, FEC120 (Burnell, SABCS 2006). We prospectively compared a sequential epirubicin-docetaxel chemotherapy regimen to FEC120. Patients and Methods:
The ADEBAR study was a multicenter phase III trial (n=1502) to evaluate whether breast cancer (BC) pts with &gt; 3 axillary lymph node metastases benefit from a sequential anthracycline-docetaxel regimen (E90C-D: 4 cycles epirubicin [E] 90 mg/m2 plus cyclophosphamide [C] 600 mg/m2 q21 days followed by 4 cycles docetaxel [D] 100mg/m2 q21 days) compared to dose-intensive anthracycline-containing polychemotherapy (FE120C: 6 cycles E 60 mg/m2 d 1+8, 5-FU 500mg/m2 d 1+8 and C 75 mg/m2 d 1–14, q4 weeks). The median follow-up time will be 60 months.
Results: Treatment was stopped prematurely in 3.7% of the pts in the E90C-D arm and in 8.0% in the FE120C arm due to toxicity (p=0.0009). Antibiotic treatment was given in 10.4% (E90C-D) vs. 19.7% (FE120C), G-CSF support in 39.2% vs 61.4% and erythropoietin stimulation in 8.7% vs. 20.0%, respectively (p&lt;0.0001). Haematological toxicity (leucopenia, neutropenic fever, thrombocytopenia, anemia) was significantly higher in the FE120C-arm.
Mature final 5-year-survival data will be presented at the SABCS meeting 2011.
Conclusion: Different toxicity profiles given, hematological toxicity in the FE120C group was more severe than in the E90C-D. Mature survival data will be discussed in this context.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD07-01.
Abstract A107: Income disparities in the receipt and adherence to adjuvant hormonal therapy in a cohort of young estrogen receptor-positive breast cancer cases
Authors: McDougall Jean A. , Li Christopher I. 
Published: June 2012

Abstract
This study aimed to investigate the relationship between income and the receipt and adherence to adjuvant hormonal therapy (AHT) in a cohort of estrogen receptor (ER)-positive, invasive breast cancer cases. Women age 20 to 45 with a first primary diagnosis of invasive breast cancer between 2004 and 2010 were identified from the Cancer Surveillance System of Western Washington and given a telephone interview to ascertain data on breast cancer risk factors, demographic characteristics, and treatment history. A total of 602 invasive ER-positive cases were available for this analysis which uses logistic regression to compare the odds of starting and discontinuing AHT, such as Tamoxifen, Letrozole, Anastrozole, or Leuprolide, by categories of annual household income adjusting for household size and age. 72% of women received any AHT and 14% of women had discontinued AHT by the time of the interview. Of those who discontinued AHT, 53% had discontinued after less than one year of starting. There were no differences in the likelihood of starting AHT by income. However, women with an income of less than $50,000 were 2.4 times more likely to report discontinuing use than women with an income of $50,000 or more (Odds ratio(OR)=2.42; 95% Confidence interval(CI)=1.32-4.41). The income disparity in the likelihood of discontinuing AHT is particularly stark when comparing women with an income of ≥$90,000 to those with an income of &lt;$25,000 (OR=4.66; 95% CI = 1.91–11.36). The financial burden of breast cancer treatment may cause women with limited resources to discontinue AHT, putting them at greater risk of poor disease outcomes.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A107.
Abstract A14: Esperanza y Vida: A community-based approach to increasing breast and cervical cancer screening for immigrant Latinas
Authors: Jandorf Lina , Thelemaque Linda , Erwin Deborah O. 
Published: June 2012

Abstract
As health disparities continue to plague our nation it is imperative that we find ways to reduce and eliminate this public health issue. Further, as Latinos have become the largest minority group in the United States, we must address disparities in breast and cervical cancer screening rates as well as find ways to successful reduce disparities in cancer survival. Breast cancer is the most frequently diagnosed cancer among Latinas; often diagnosed at advanced stages. The incidence rates for cervical cancer are higher than non-Latina white women. Latinas have faced many difficulties within the medical care system, including accessing health services. Patient navigation has become increasingly common as a way to increase adherence to treatment and more recently, as a method of increasing cancer screening. Esperanza y Vida was developed as an intervention to reach groups of women from diverse Latino backgrounds, as a culturally and linguistically appropriate approach to cancer education and screening. Following the educational component of the program, women were contacted 2-months later to determine their age-specific screening adherence status (mammography, clinical breast exam and/or Pap test). Women who were still non-adherent to screening were offered navigational assistance. Navigational services included assistance in locating bilingual services as well as free and/or low cost screening programs, logistical assistance, encouragement for screening and additional education about the importance of screening. All women were again contacted 8 months post the educational program. This presentation will focus on the outcomes following navigation. The sample included women who were reached for both the 2- and 8-month follow up assessments and received navigational services. We will demonstrate the success of navigation; of women who were non-adherent to mammography, 63% became adherent. Univariate predictors include where the programs were conducted (Arkansas, New York City and Western NY) and concurrent screening. For clinical breast exams, 61% of non-adherent women became adherent with significant predictors of program location, years living in the US, conducting breast self exams, and concurrent other screening. For Pap test, 59% of the women became adherent with significant predictors of program location, marital status, current screening and not being afraid of hear the results of medical exams. In multiple regression analyses, significant predictors of each screening test included adherence to the other screening exams, at the same time point. This is very encouraging, in that it appears that once we can connect women with clinical services, they are able to access other exams. Next steps include understanding why 40% of women still remained unscreened.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A14.
Abstract A24: Does patient navigation improve time to diagnostic resolution of abnormal mammograms among depressed urban women?
Authors: Kronman Andrea C. , De La Cruz Ignacio I. , Freund Karen M. , Heeren Tim , Battaglia Tracy A. 
Published: June 2012

Abstract
Background: Depression is more common in women, lower socio-economic groups, certain racial/ethnic minorities, and is associated with higher breast cancer mortality. Patient navigation has been shown to improve access to timely cancer care in a patient-centered manner, by identifying and helping to overcome barriers to healthcare. Our objective is to determine if patient navigation improves time to diagnostic resolution after abnormal mammograms for vulnerable women who are depressed.
Methods: The Boston University Patient Navigator Research Program provided navigation for all patients who had an abnormal screening mammogram in 3 affiliated community health center (CHC) 2007–2008, with 3 CHCs serving as control sites and receiving usual care. A woman was categorized as “depressed” if depression was recorded in her medical record during the 12 months preceding the screening test abnormality. All women were followed for 12 months to determine if they completed diatnostic evaluation. Demographic characteristics of depressed and non-depressed women were compared through chi-square tests. Differences in the percent of women who did not complete diagnostic evaluation within 12 months for depressed vs. non-depressed women, and for navigated vs. control women, were tested through chi-square and described through odds ratios and 95% confidence intervals.
Results: Among 1299 women with abnormal mammograms, 17% were depressed, 12% had anxiety. Most of the women were non-White: 28% Hispanic, 35% Black, and 11% Vietnamese; English was the primary language in 58%, and less than one third had private health care insurance. Depression was positively associated with white race and Hispanic ethnicity (P &lt; 0.01), English and Spanish language (P &lt;0.001), older age (P =0.03), anxiety (P &lt; 0.001), and public health insurance status (P &lt; 0.001); and negatively associated with no insurance status (P &lt; 0.001). Among controls, there was a suggestion that non-depressed women were more likely to complete diagnostic resolution compated to depressed women (14% vs. 8%, OR 1.95 (0.94, 4.03), p=0.072). Among depressed women, those who were navigated were significantly more likely to complete diagnostic resolution (14% vs. 5%, OR 3.24 (1.03, 12.26), p=0.046).
Depression is common in women needing diagnostic testing for abnormal cancer screening, and depressed women may particularly benefit from patient navigation.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A24.
Abstract A4: Integrative genomic analysis of lung cancer: Focus on health disparities
Authors: Robles Ana I. , Mathé Ewy , Bowman Elise D. , Ryan Brid M. , Haznadar Majda , Harris Curtis C. 
Published: June 2012

Abstract
Racial differences in the incidence and mortality of lung cancer are well documented. Many factors are known to influence the risk and outcome of this most deadly disease, including exposure, behavior, access to health care, as well as inherent susceptibility. There is a paucity of data regarding the existence, if any, of biological differences among tumors that reflect inherent susceptibilities to known etiological factors and may contribute to some of the disparities observed among African Americans and Caucasians. Our laboratory employs a multipronged strategy to study the interaction of genetic, molecular, and etiological factors leading to lung cancer risk and survival, that encompasses mRNA and microRNA (miRNA) expression, DNA methylation, metabolomics, as well as genetic susceptibility in the form of Single Nucleotide Polymorphisms (SNPs). In this study, a cohort of sixty paired cancerous/non-cancerous lung tissues excised from stage I lung cancer patients (16 African Americans and 48 Caucasians) recruited through our longstanding Case-Control Study at University of Maryland, Baltimore, are being characterized by miRNA quantitation (Nanostring nCounter Human miRNA Expression Assay), mRNA expression profiling (Illumina HumanRef-8 v3 Expression Beadchip arrays), and methylation profiling (Illumina Infinium Human Methylation27 Beadchip arrays). When gene expression profiles on cancerous tissues from African Americans and Caucasians were compared, three genes were differentially expressed (FDR&lt;10%), namely CRYBB2, PPIL3, and COMMD5. A similar comparison on non-cancerous tissues yielded 12 genes (FDR&lt;10%), which included CRYBB2 and PPIL3. CRYBB2, Crystalline Beta B2, has previously been associated with prostate cancer in African Americans, and is upregulated in this sample cohort. We are currently analyzing and integrating these different data types with the purpose of finding biomarkers for lung cancer prognosis, associating DNA methylation, mRNA and miRNA abundance with clinical features of lung cancer (including race, gender, histology, and smoking), and correlating methylation, mRNA and miRNA patterns. Our goal is to delineate the most important transcriptional networks operational in lung cancer and specifically focus on those that may illuminate racial disparities associated with this disease.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A4.
Abstract A50: Targeting nanotherapeutics for breast, ovarian, and prostate cancer
Authors: Olivos David John , Saunders Mary R. , Ramirez Laura , Banford Nicholas , Quattrocchi Julie-Marie , Lam Kit S. 
Published: June 2012

Abstract
African Americans have the highest incidence and mortality rates from cancer despite representing a minority of the population of the United States. In particular, breast and prostate cancer significantly contribute to these disproportionate rates in African American women and men respectively compared to other ethnic groups. We have developed a series of novel self-folding combinatorial libraries composed of cholic acid or cholesterol functional groups with single and branched hexamer peptide arms. Fixed hydrophobic amino acids near the N-terminus (position 5) of the peptide arms interact with the hydrophobic face of the planar cholic acid or cholesterol molecule to form 3-Dimensional compact molecules offering a variety of unique peptide sequence presentations. Receptors overexpressed on cancerous cells serve as the targets for these synthetic molecules. Screening of One-Bead One-Compound (OBOC) combinatorial libraries under stringent conditions provides a powerful approach to test hundreds of thousands to millions of compounds in one batch. Novel cholic-peptide hybrid molecules containing RGD motifs binding to vβ3 integrin were discovered against MDA-MB-231 breast cancer. An NGR motif known to target receptors up regulated in the tumor vasculature and perivascular cells were found in cholesterol-peptide protein conformation mimetics binding to A2780 chemo-resistant ovarian cancer. Targeting ligands to PC3N and LnCap prostate cancers from both cholesterol and cholic acid library sets were discovered. Based on these findings, focused libraries were constructed and screened for enhanced affinity and specificity. Candidate peptidomimetics are equipped on our novel cholic acid nanocarriers enhancing nanotherapeutic targeting, efficacy, and limiting toxicity. The reduced toxicity stemming from tumor targeting and increased efficacy from the combination of nanocarrier EPR effects and targeting ligands result in longer, more tolerable therapeutic cycles that might significantly extend the life expectancy and quality of life of breast and prostate cancer in patients, for which current treatment options are ineffective. Developing novel treatment strategies which include the selective delivery of cytotoxic agents for the treatment of cancers disproportionately afflicting minority populations may be translated for clinical development as a promising diagnostic and therapeutic tools.
Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A50.